This research is Trending!
New Evidence in Heart Failure: 2026 Update
Key result
Recent diagnostic and therapeutic advances drive a shift toward personalized and biologically informed HF care.
Why the study?
Heart failure remains a major cause of morbidity, mortality, and healthcare expenditure with an increasing global burden, alongside an accelerating pace of scientific progress across epidemiology, diagnostics, and management.
Key Points
- Provide a comprehensive update on evolving epidemiology, pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic paradigms in heart failure management.
- Synthesized contemporary evidence on heart failure classification, including heart failure with reduced and preserved ejection fraction.
- Evaluated diagnostic tools spanning artificial intelligence, multi-omics, advanced imaging, and disease-specific aetiologies.
- Reviewed novel pharmacotherapies including sodium-glucose cotransporter-2 inhibitors, finerenone, and incretin-based agents.
- Mechanistic research underscores the central roles of chronic inflammation, immune activation, metabolic dysfunction, and multi-organ cross-talk in disease progression.
- Therapeutic advances have expanded treatment options across ejection fraction spectra through guideline-directed medical therapy, novel metabolic modulators, and transcatheter interventions.
- Modern management is shifting from empirical ejection fraction classification toward individualized, biologically guided interventions to improve outcomes.
PICO
P
Population
Heart failure
Recent advances in heart failure epidemiology, diagnostics, and therapeutics support a transition towards a more personalized and biologically informed model of care across the entire HF spectrum.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The mildly reduced LVEF phenotype was introduced in previous guidelines to focus on patients not usually included in clinical trials. Education and lifestyle advice empower patients to manage their heart failure and engage in shared decision-making.”
“There's a reclassification of the nomenclature. We're not using any more reduced or mildly reduced or preserved rejection fraction, we're now going reduce EF less than 50% ejection fraction or preserve ejection fraction more than 50%. Also, there is a new nomenclature for drug therapies... we're not seeing any more guideline or medical therapy, there's now foundational medical therapies.”
Implication
May guide future personalized HF strategies; leaves open the need for prospective validation across phenotypes.
Abstract
Heart failure (HF) remains a major cause of morbidity, mortality, impaired quality of life and healthcare expenditure worldwide. The global burden of HF continues to increase due to population aging, improved survival, and the growing prevalence of cardiovascular, renal, and metabolic comorbidities. Simultaneously, the pace of scientific progress in HF has accelerated considerably. Recent advances have refined our understanding of HF epidemiology, prognosis, and disease trajectories, including emerging concepts of HF improvement, remission, and recovery. The Second Universal Definition of HF has also updated the classification framework, moving beyond the traditional ejection fraction-based categories. HF is now broadly classified into two major phenotypes: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Novel mechanistic insights highlight the role of inflammation, immune activation, metabolic dysfunction, mitochondrial biology, and multisystem interactions in HF progression. There has also been significant progress in the characterization and management of major comorbidities, including chronic kidney disease (CKD), diabetes, obesity, atrial fibrillation (AF), pulmonary hypertension, frailty, malnutrition, and cancer. Diagnostic innovations include novel biomarkers, multi-omics technologies, artificial intelligence-based approaches, advanced imaging techniques, congestion assessment tools, and emerging digital health solutions. Important advances have occurred in specific HF aetiologies, including cardiomyopathies, cardiac amyloidosis (CA), myocarditis, arrhythmia-induced cardiomyopathy (AiCM), and Chagas cardiomyopathy. Therapeutic developments continue to reshape HF management across the spectrum of left ventricular ejection fraction. Recent evidence has focused on optimization of guideline-directed medical therapy in HFrEF, expansion of evidence-based therapies in HFpEF, and growing roles for sodium–glucose cotransporter-2 inhibitors, finerenone, incretin-based therapies, and transcatheter valve interventions. Collectively, these advances support the transition from a predominantly phenotype-based approach towards a more personalized and biologically informed model of HF care, with the potential to further improve outcomes across the entire HF spectrum.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Liguori et al. (2026) conducted a review in Heart failure. Recent advances in heart failure diagnostics and therapeutics support a transition toward a more personalized and biologically informed model of care.